ANTISENSE INHIBITION OF FUNGAL GROWTH

Information

  • Research Project
  • 3489784
  • ApplicationId
    3489784
  • Core Project Number
    R43AI034654
  • Full Project Number
    1R43AI034654-01
  • Serial Number
    34654
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1993 - 31 years ago
  • Project End Date
    5/31/1994 - 30 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1993 - 31 years ago
  • Budget End Date
    5/31/1994 - 30 years ago
  • Fiscal Year
    1993
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/29/1993 - 31 years ago
Organizations

ANTISENSE INHIBITION OF FUNGAL GROWTH

Immunocompromised patients provide perhaps the greatest challenge to modern health care for patients are susceptible to infections by organisms that are normally harmless commensals. Treatment of fungal infections is difficult due to a lack of effective antifungal antibiotics. Even after 29 years of use, Amphotericin is still the drug of choice to treat systemic fungal infections; however, amphotericin is very toxic to human cells. Other antifungal agents are limited by either a narrow spectrum of activity or by toxicity or both. One striking difference between fungal and human cells is that fungal cells are encased in a wall which protects them a hostile external environment. Human pathogenic fungi contain chitin, (1-3)-beta-glucan, other glucans, peptides, and lipids as essential components of cell walls. All available information indicates that (1-3)-beta-glucan synthase activity is very important for fungal cell-wall assembly. We will form antisense constructs of a gene that codes for an essential component of beta(1,3)glucan synthase activity. We will transform fungal cells with antisense constructs and determine the effect of expression of antisense RNA on enzyme activity and fungal growth. We expect that antisense oligonucleotides may be important, novel therapeutic agents directed specifically against fungi.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    MYCOLOGICS, INC.
  • Organization Department
  • Organization DUNS
    190042098
  • Organization City
    AURORA
  • Organization State
    CO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    80045
  • Organization District
    UNITED STATES